Keyword: NewLink Genetics
Merck kicked off a rolling FDA submission for its Ebola vaccine that's already been deployed against outbreaks in the Democratic Republic of Congo.
The U.S. government is committing millions of dollars in support for leading Ebola vaccine programs at Merck and Johnson & Johnson.
A new U.S. study shows that Merck's Ebola vaccine rVSV-ZEBOV offers protection that can last for at least a year.
A shareholder is taking it to the company’s current and former execs for “gross mismanagement” and other allegations.
On the heels of crushing Phase III results for its pancreatic cancer candidate, NewLink Genetics has won a lifeline from the U.S. government. The biotech nabbed up to $76 million in BARDA funding to advance its Merck-licensed Ebola vaccine.
On the heels of devastating Phase III trial results for its pancreatic cancer vaccine, NewLink Genetics will undergo a restructuring, downsizing by 100 employees, reducing manufacturing capacity and lowering its headquarters space.
NewLink Genetics is heating up as it bags a $2.8 million contract from the DOD’s Defense Threat Reduction Agency to develop a multivalent filovirus vaccine.